Effects and mechanisms of <i>Helicobacter pylori</i> on cancers development and immunotherapy.

And in KEYNOTE-062 trial, pembrolizumab demonstrated clinically meaningful efficacy in patients with a CPS of 10 or higher for PD-L1, with better survival in patients with high PD-L1 expression, indicating that patients with higher levels of PD-L1 expression showed a trend toward better survival ( 42 , 43 ).

also in 53,322 other papers